- Home
- STHO vs ATOS Comparison
STHO vs ATOS Comparison
Compare STHO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- ATOS
- Stock Information
- Founded
- STHO N/A
- ATOS 2009
- Country
- STHO United States
- ATOS United States
- Employees
- STHO N/A
- ATOS N/A
- Industry
- STHO Real Estate
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- ATOS Health Care
- Exchange
- STHO Nasdaq
- ATOS Nasdaq
- Market Cap
- STHO 173.3M
- ATOS 149.7M
- IPO Year
- STHO N/A
- ATOS 2012
- Fundamental
- Price
- STHO $13.77
- ATOS $1.52
- Analyst Decision
- STHO
- ATOS Strong Buy
- Analyst Count
- STHO 0
- ATOS 3
- Target Price
- STHO N/A
- ATOS $6.25
- AVG Volume (30 Days)
- STHO 30.5K
- ATOS 535.6K
- Earning Date
- STHO 08-06-2024
- ATOS 08-12-2024
- Dividend Yield
- STHO N/A
- ATOS N/A
- EPS Growth
- STHO N/A
- ATOS N/A
- EPS
- STHO N/A
- ATOS N/A
- Revenue
- STHO $136,773,000.00
- ATOS N/A
- Revenue This Year
- STHO N/A
- ATOS N/A
- Revenue Next Year
- STHO N/A
- ATOS N/A
- P/E Ratio
- STHO N/A
- ATOS N/A
- Revenue Growth
- STHO 38.53
- ATOS N/A
- 52 Week Low
- STHO $10.76
- ATOS $0.62
- 52 Week High
- STHO $15.31
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- STHO 60.91
- ATOS 66.31
- Support Level
- STHO $12.69
- ATOS $1.30
- Resistance Level
- STHO $13.07
- ATOS $1.46
- Average True Range (ATR)
- STHO 0.29
- ATOS 0.07
- MACD
- STHO 0.00
- ATOS 0.02
- Stochastic Oscillator
- STHO 87.75
- ATOS 100.00
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.